Structure Therapeutics Inc. (GPCR) Stock

About Structure Therapeutics Inc.

Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.

Structure Therapeutics Inc. is headquartered in US.

Structure Therapeutics Inc. (GPCR) stock trades at $53.36 with a market capitalization of $3.07B. The stock is valued at a negative price-to-earnings (P/E) ratio of -20.21, reflecting a net loss over the last twelve months, price-to-book of 2.67, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $15.80 and $94.90, and currently trades 43.8% below its 52-week high.

On profitability, Structure Therapeutics Inc. generates a return on equity (ROE) of -15.14% (negative, reflecting a net loss), return on capital employed of -14.46%.

Official website: structuretx.com

Structure Therapeutics Inc. by the numbers, 2020–2025

Between 2020 and 2025 Structure Therapeutics Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-141.0M.

On a trailing twelve-month basis to Mar '26, revenue is $0 and net profit $-171.0M.

Borrowings stand at $6.0M, cash on hand is $1.5B, cash from operations was $-222.0M in the latest year, positive in 0 of the last 6.

Return on equity has averaged 12.5% over five years, and was -9.3% in the most recent year.

The share price itself has compounded at —% a year over five years, 17.1% over three, 182.3% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Structure Therapeutics Inc. (GPCR) — frequently asked questions